Incyte (NASDAQ:INCY) Price Target Raised to $123.00 at Stifel Nicolaus

Incyte (NASDAQ:INCY) had its price objective increased by Stifel Nicolaus from $120.00 to $123.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock.

Several other equities analysts have also recently issued reports on INCY. Weiss Ratings upgraded shares of Incyte from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday, April 1st. Oppenheimer boosted their target price on shares of Incyte from $84.00 to $90.00 and gave the company a “market perform” rating in a research note on Wednesday. Morgan Stanley set a $102.00 target price on shares of Incyte in a research note on Wednesday, February 11th. Piper Sandler boosted their target price on shares of Incyte from $102.00 to $110.00 and gave the company an “overweight” rating in a research note on Friday, February 6th. Finally, Wells Fargo & Company decreased their target price on shares of Incyte from $107.00 to $101.00 and set an “equal weight” rating for the company in a research note on Wednesday, February 11th. Ten analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $104.26.

Incyte Stock Performance

Shares of NASDAQ INCY opened at $99.10 on Wednesday. The company has a current ratio of 3.32, a quick ratio of 3.25 and a debt-to-equity ratio of 0.01. Incyte has a 12 month low of $57.77 and a 12 month high of $112.29. The company has a 50 day simple moving average of $95.84 and a two-hundred day simple moving average of $98.76. The stock has a market cap of $19.72 billion, a price-to-earnings ratio of 15.46, a PEG ratio of 0.77 and a beta of 0.85.

Incyte (NASDAQ:INCY) last announced its quarterly earnings data on Tuesday, April 28th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.34 by $0.47. Incyte had a net margin of 25.03% and a return on equity of 26.34%. The business had revenue of $1.27 billion during the quarter, compared to analysts’ expectations of $1.23 billion. During the same period in the previous year, the business posted $1.16 EPS. The business’s quarterly revenue was up 20.9% compared to the same quarter last year. As a group, analysts predict that Incyte will post 6.46 earnings per share for the current year.

Insider Activity

In other news, insider Pablo J. Cagnoni sold 18,667 shares of the company’s stock in a transaction on Friday, April 17th. The shares were sold at an average price of $96.50, for a total transaction of $1,801,365.50. Following the completion of the sale, the insider owned 262,692 shares of the company’s stock, valued at $25,349,778. This represents a 6.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 17.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Incyte

Large investors have recently modified their holdings of the business. Harbor Capital Advisors Inc. purchased a new stake in shares of Incyte during the third quarter worth $26,000. Root Financial Partners LLC purchased a new stake in shares of Incyte during the third quarter worth $28,000. Elyxium Wealth LLC purchased a new stake in shares of Incyte during the fourth quarter worth $28,000. Smithfield Trust Co grew its holdings in shares of Incyte by 135.0% during the fourth quarter. Smithfield Trust Co now owns 282 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 162 shares in the last quarter. Finally, Quent Capital LLC purchased a new stake in shares of Incyte during the third quarter worth $30,000. Hedge funds and other institutional investors own 96.97% of the company’s stock.

More Incyte News

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Q1 beat — Incyte reported Q1 EPS and revenue above expectations ($1.81 EPS; $1.27B revenue), driven by Jakafi and Opzelura strength, which supports near-term cash flow and investor confidence. Reuters: Incyte beats first-quarter estimates
• Positive Sentiment: Commercial outlook & launches — Management outlined 2026 net sales guidance in the ~$4.77B–$4.94B range and said it’s preparing four product launches over the next 12 months, indicating multiple growth catalysts beyond the core franchise. Seeking Alpha: Incyte outlines 2026 net sales and launches
• Positive Sentiment: Analyst lift — Stifel raised its price target to $123 and maintained a Buy, providing fresh upside thesis and likely supporting demand for the shares. Benzinga: Stifel raises price target
• Positive Sentiment: Investor outreach — Incyte announced presentations at upcoming investor conferences, which can increase visibility and help clarify commercialization plans. Business Wire: Investor conferences
• Neutral Sentiment: Executive change — Incyte appointed Suketu (Suky) Upadhyay as CFO; leadership continuity matters but is not an immediate earnings driver. Yahoo Finance: CFO appointment
• Neutral Sentiment: Clinical readouts — The company posted Phase 3 vitiligo wins for its JAK inhibitor, but competitive pressure from established rivals (e.g., Rinvoq) leaves market-share outcomes uncertain. FierceBiotech: JAK inhibitor results
• Negative Sentiment: Guidance gap — The company’s 2026 revenue range was below some street estimates (consensus higher), which raises questions about how quickly launches will offset patent/market pressures; this likely tempered upside despite the quarter beat. Seeking Alpha: Guidance and sales outlook
• Negative Sentiment: Regulatory/marketing scrutiny — The FDA criticized past promotional claims around Niktimvo, a reputational and compliance risk that could lead to tighter oversight or remediation costs. FiercePharma: FDA criticism

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.